ADMA Biologics Inc vs Western Digital Corp — how do they compare? ADMA Biologics Inc trades at $9.94 (market cap $2.22B), while Western Digital Corp trades at $458.24 (market cap $150.95B). The key difference: Western Digital Corp is far larger — about 68× ADMA Biologics Inc's market cap, and Western Digital Corp pays a 0.14% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WDC | |
|---|---|---|
Market Cap | $2.22B | $150.95B |
Sector | Health | Technology |
52-Week High | $20.38 | $746.23 |
52-Week Low | $7.60 | $74.66 |
Enterprise Value | $2.29B | $150.42B |
Dividend Yield | — | 0.14% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Western Digital (WDC) trades at $438.12, up 0.88% on the day, with strong recent earnings performance beating expectations for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 72.95% net income margin and 131.02% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, though the stock faces valuation concerns after recent sell-offs.
The outlook remains positive with 72% analyst buy ratings and $665 consensus price target, representing 52% upside potential. Key risks include stretched valuation metrics (P/E 18.04, EV/EBITDA 30.24) and competitive threats from SSD adoption. The company's strong AI storage positioning and margin expansion provide growth opportunities, but investors should monitor execution against high expectations.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →